Myoblast cell transplant therapy

Drug Profile

Myoblast cell transplant therapy

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator GenVec
  • Developer Astellas Pharma
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Heart-failure in USA (Intracardiac, Injection)
  • 14 Nov 2014 Advanced Cell Technology is now called Ocata Therapeutics
  • 03 Nov 2010 Advanced Cell Technology receives a US Federal grant under Patient Protection and Affordable Care Act of 2010 for its blastomere, myoblast, retinal pigment epithelium, and induced pluripotent stem cells programmes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top